Loading clinical trials...
Loading clinical trials...
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer
Conditions
Interventions
epothilone b
Locations
8
United States
UCLA Medical Center
Los Angeles, California, United States
University of Maryland
Baltimore, Maryland, United States
Wayne State University Karmanos Cancer Center
Detroit, Michigan, United States
Our Lady Of Mercy Medical Center
The Bronx, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Washington
Seattle, Washington, United States
Start Date
April 1, 2002
Primary Completion Date
August 1, 2003
Last Updated
April 17, 2012
NCT00033137
NCT07225114
NCT06680089
NCT05917106
NCT06536439
NCT03091192
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions